CD4 and renal cell carcinoma: In renal cell carcinoma (RCC) patients, IFN-DC were described to promote significantly higher numbers of autologous cytotoxic antitumor responses in vitro, as compared to classic DC, as well as to reduce regulatory-type T cells (Tregs) among CD4+ T-cell responder populations [57].